Skip to main content

Schrodinger, Inc. (SDGR)

NASDAQ: SDGR · IEX Real-Time Price · USD
55.80
+0.44 (0.80%)
After-hours:Oct 15, 2021 7:25 PM EDT
55.36
0.35 (0.64%)
At close: Oct 15, 4:00 PM
Market Cap3.92B
Revenue (ttm)120.74M
Net Income (ttm)-41.96M
Shares Out70.58M
EPS (ttm)-0.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume397,228
Open55.75
Previous Close55.01
Day's Range54.37 - 55.75
52-Week Range47.59 - 117.00
Betan/a
AnalystsBuy
Price Target87.60 (+58.2%)
Est. Earnings DateNov 11, 2021

About SDGR

Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharma...

IndustryHealth Care Technology
IPO DateFeb 6, 2020
Employees445
Stock ExchangeNASDAQ
Ticker SymbolSDGR
Full Company Profile

Financial Performance

In 2020, Schrodinger's revenue was $108.10 million, an increase of 26.36% compared to the previous year's $85.54 million. Losses were -$24.46 million, -0.44% less than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Schrodinger stock is "Buy." The 12-month stock price forecast is 87.60, which is an increase of 58.24% from the latest price.

Price Target
$87.60
(58.24% upside)
Analyst Consensus: Buy

News

MD Anderson and Schrödinger Announce Strategic Research Collaboration to Accelerate Development of WEE1 Program

HOUSTON & NEW YORK--(BUSINESS WIRE)--MD Anderson and Schrödinger today announced a strategic research collaboration to accelerate the development of Schrödinger's WEE1 Inhibitor Program.

1 week ago - Business Wire

This Healthcare Company Is Using AI to Develop Drugs

Could this technology be the future of the pharmaceutical industry?

1 week ago - The Motley Fool

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).

3 weeks ago - Business Wire

One Stock to Dominate Biotech

The amazing biotech advancements coming this decade… breakthroughs in drug discovery… the unrivaled leader in the space from Luke Lango… how it becomes a 10X winner   In early January 2020, the Harvard ...

1 month ago - InvestorPlace

Schrödinger to Present at Four Investor Conferences in September

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will present at four investor conferences in September.

1 month ago - Business Wire

Why Schrödinger Shares Are Rising

Schrödinger Inc (NASDAQ: SDGR) shares are trading higher by 4.8% at $62.58 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and announced an $82 price target. Schrödinger shares w...

1 month ago - Benzinga

4 Specialized AI Stocks to Buy for the Boom

Companies with focused AI technologies appear to be doing better than firms with AI based on general data. Here are four AI stocks to buy.

Other symbols:ICADPLTRUPST
1 month ago - InvestorPlace

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).

1 month ago - Business Wire

Schrödinger Stock Is Trading Lower After Reporting Deeper Than Expected Q2 Loss

Schrödinger Inc (NASDAQ: SDGR) has reported Q2 revenues of $29.78 million, +29% Y/Y, slightly missing the consensus of $29.88 million. Software revenue was $24.1 million, +15%.

2 months ago - Benzinga

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -68.97% and -1.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: Schrodinger Q2 Earnings

Shares of Schrodinger (NASDAQ:SDGR) decreased 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 880.00% over the past year to ($0.49), whic...

2 months ago - Benzinga

Schrödinger Reports Second Quarter 2021 Financial Results and Provides Company Update

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported financial results for the second quarter of 2021 and provided a company update.

2 months ago - Business Wire

Is a Surprise Coming for Schrodinger (SDGR) This Earnings Season?

Schrodinger (SDGR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

4 Mid-Cap Stocks to Buy Ahead of Earnings Results This week

The four mid-cap stocks discussed here are slated to release earnings results this week. These are CACI, SDGR, AVT and GRWG.

Other symbols:AVTCACIGRWG
2 months ago - Zacks Investment Research

Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Schrodinger, Inc. (SDGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology

NEW YORK & SHANGHAI & SAN FRANCISCO--(BUSINESS WIRE)--Schrödinger and Zai Lab today announced a global R&D collaboration in oncology.

Other symbols:ZLAB
2 months ago - Business Wire

Schrödinger to Host Conference Call to Discuss Second Quarter 2021 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will report second quarter 2021 financial results on August 12, 2021.

2 months ago - Business Wire

Schrodinger (SDGR) Sees Hammer Chart Pattern: Time to Buy?

Schrodinger (SDGR) has been struggling lately, but the selling pressure may be coming to an end soon.

2 months ago - Zacks Investment Research

Schrödinger Hosts First Annual Educator's Day and Announces “Teaching with Schrödinger” Program

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will host its first annual Educator's Day and "Teaching with Schrödinger" Program.

2 months ago - Business Wire

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).

2 months ago - Business Wire

Schrödinger to Present at Two Virtual Investor Conferences in July

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will present at two investor conferences in July.

3 months ago - Business Wire

The 1 Stock I'd Buy Right Now

I'm confident that Schrodinger will be a 10-bagger over the next decade. And it might go up a lot more than that.

Other symbols:OPRXROKUSESHOPSISQ
3 months ago - The Motley Fool

My Favorite Biotech Stock Right Now

I'm an owner of Schrodinger because this company's software is revolutionizing drug discovery, and it's going to be a monster stock over the next decade.

Other symbols:VEEV
3 months ago - The Motley Fool

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported Inducement Grants under Nasdaq Listing Rule 5635(c)(4).

3 months ago - Business Wire

7 Stocks To Buy if You're Trying to Double Your Money in 2021

Searching for stocks to buy that could legitimately double before 2022? These seven are in position to do just that.

4 months ago - InvestorPlace